Drug interactions in transplant patients: what everyone should know

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Current opinion in nephrology and hypertension

• Publication date

  2009-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/MNH.0b013e32832edcb2PMID 19593130
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics of mood stabilizers and new anticonvulsants.

  2025cited by this paper
• Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus.

  2009cited by this paper
• Comedication of caspofungin acetate and cyclosporine A after allogeneic haematopoietic stem cell transplantation leads to negligible hepatotoxicity

  2008cited by this paper
• No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients

  2008cited by this paper
• Lack of Pharmacokinetic Interaction Between Anidulafungin and Tacrolimus

  2007cited by this paper
• Carvedilol increases ciclosporin bioavailability by inhibiting P‐glycoprotein‐mediated transport

  2007cited by this paper
• Effect of Highly Active Antiretroviral Therapy on Tacrolimus Pharmacokinetics in Hepatitis C Virus and HIV Co-Infected Liver Transplant Recipients in the ANRS HC-08 Study

  2007cited by this paper
• Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: efficacy and concomitant cyclosporin A

  2007cited by this paper
• Effect of Oral Posaconazole on the Pharmacokinetics of Cyclosporine and Tacrolimus

  2007cited by this paper
• Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.

  2006cited by this paper
• Change of the blood concentration of tacrolimus after the switch from fluconazole to voriconazole in patients receiving allogeneic hematopoietic stem cell transplantation.

  2006cited by this paper
• Multidrug Resistance Protein 2 Genetic Polymorphisms Influence Mycophenolic Acid Exposure in Renal Allograft Recipients

  2006cited by this paper
• Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation.

  2006cited by this paper
• ROLE OF MRP2 IN THE HEPATIC DISPOSITION OF MYCOPHENOLIC ACID AND ITS GLUCURONIDE METABOLITES: EFFECT OF CYCLOSPORINE

  2006cited by this paper
• Factors Influencing the Magnitude and Clinical Significance of Drug Interactions Between Azole Antifungals and Select Immunosuppressants

  2006cited by this paper
• Safety Profile of Concomitant Use of Caspofungin and Cyclosporine or Tacrolimus in Liver Transplant Patients

  2006cited by this paper
• The Effect of β-Blocker Use on Cyclosporine Level in Cardiac Transplant Recipients

  2005cited by this paper
• Combined Therapy with Atorvastatin and Calcineurin Inhibitors: No Interactions with Tacrolimus

  2005cited by this paper
• IDENTIFICATION OF THE UDP-GLUCURONOSYLTRANSFERASE ISOFORMS INVOLVED IN MYCOPHENOLIC ACID PHASE II METABOLISM

  2005cited by this paper
• Drug interaction between mycophenolate mofetil and rifampin: Possible induction of uridine diphosphate‐glucuronosyltransferase

  2005cited by this paper
• Cyclosporine Pharmacokinetics and Dosing Modifications in Human Immunodeficiency Virus-Infected Liver and Kidney Transplant Recipients

  2005cited by this paper
• The Influence of Norfloxacin and Metronidazole on the Disposition of Mycophenolate Mofetil

  2005cited by this paper
• Cyclosporine Interacts with Mycophenolic Acid by Inhibiting the Multidrug Resistance‐Associated Protein 2

  2005cited by this paper
• Assessment of the Safety and Pharmacokinetics of Anidulafungin When Administered With Cyclosporine

  2005cited by this paper
• Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A

  2004cited by this paper
• A PROSPECTIVE, RANDOMIZED STUDY OF COADMINISTRATION OF KETOCONAZOLE AND CYCLOSPORINE A IN KIDNEY TRANSPLANT RECIPIENTS: TEN-YEAR FOLLOW-UP

  2004cited by this paper
• Management of drug‐to‐drug interactions between cyclosporine A and the protease‐inhibitor lopinavir/ritonavir in liver‐transplanted HIV‐infected patients

  2004cited by this paper
• Cyclosporin A, but Not Tacrolimus, Inhibits the Biliary Excretion of Mycophenolic Acid Glucuronide Possibly Mediated by Multidrug Resistance-Associated Protein 2 in Rats

  2004cited by this paper
• The effect of beta-blocker use on cyclosporine level in cardiac transplant recipients.

  2004cited by this paper
• Protease inhibitors and diltiazem increase tacrolimus blood concentration in a patient with renal transplantation: a case report

  2004cited by this paper
• Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections

  2004cited by this paper
• Fungal infections in the recipients of solid organ transplantation.

  2003cited by this paper
• Efficacy and safety of low-dose ketoconazole (50 mg) to reduce the cost of cyclosporine in renal allograft recipients.

  2003cited by this paper
• Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients

  2003cited by this paper
• Tacrolimus and Lopinavir/Ritonavir Interaction in Liver Transplantation

  2003cited by this paper
• Phenytoin Decreases the Blood Concentrations of Sirolimus in a Liver Transplant Recipient: A Case Report

  2003cited by this paper
• B19 virus infection in renal transplant recipients.

  2003cited by this paper
• Fungal Infections in Solid Organ Transplant Patients

  2003cited by this paper
• Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients

  2003cited by this paper
• New antifungal agents.

  2003cited by this paper
• Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: A case report

  2002cited by this paper
• Nefazodone and cyp450 3a4 interactions with cyclosporine and tacrolimus1.

  2002cited by this paper
• Infections in the transplant recipient.

  2002cited by this paper
• The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients

  2002cited by this paper
• Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients

  2002cited by this paper
• Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A.

  2002cited by this paper
• Pharmacokinetic Interaction Between Tacrolimus and Diltiazem

  2002cited by this paper
• Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients.

  2002cited by this paper
• Rhodococcus equi infection in transplant recipients: a case of mistaken identity and review of the literature

  2002cited by this paper
• Comparison of the Effects of Tacrolimus and Cyclosporine on the Pharmacokinetics of Mycophenolic Acid

  2001cited by this paper
• Pharmacokinetic interaction between single oral doses of ditiazem and sirolimus in healthy volunteers

  2001cited by this paper
• Active secretion and enterocytic drug metabolism barriers to drug absorption.

  2001cited by this paper
• MECHANISMS AND CONSEQUENCES OF ARTERIAL HYPERTENSION AFTER RENAL TRANSPLANTATION

  2001cited by this paper
• Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.

  2001cited by this paper
• The Gut as a Barrier to Drug Absorption

  2001cited by this paper
• Infections in recipients of kidney transplants.

  2001cited by this paper
• Tacrolimus (FK 506) in kidney transplantation: five-year survival results of the U.S. multicenter, randomized, comparative trial.

  2001cited by this paper
• Aspergillosis case-fatality rate: systematic review of the literature.

  2001cited by this paper
• Lack of citalopram effect on the pharmacokinetics of cyclosporine.

  2001cited by this paper
• The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes.

  2001cited by this paper
• Depressive symptoms and kidney transplant outcome.

  2001cited by this paper
• Coadministration of ketoconazole and cyclosporine for kidney transplant recipients: long-term follow-up and study of metabolic consequences.

  2001cited by this paper
• Human Drug Metabolism and the Cytochromes P450: Application and Relevance of In Vitro Models

  2001cited by this paper
• Is it time for ACE inhibitors in chronic allograft nephropathy?

  2000cited by this paper
• Clinical pharmacology of new antiepileptic drugs.

  2000cited by this paper
• Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: Focus on venlafaxine

  2000cited by this paper
• Does differing metabolism by cytochrome P450 have clinical importance?

  2000cited by this paper
• Cyclosporine-drug interactions and the influence of patient age.

  2000cited by this paper
• Renal Allograft Dysfunction Associated with Rifampin–Tacrolimus Interaction

  2000cited by this paper
• Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV).

  2000cited by this paper
• Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation.

  1999cited by this paper
• A Practical Guide to the Management of Hypertension in Renal Transplant Recipients

  1999cited by this paper
• Effect of Short-Term Rifampin on Stable Cyclosporine Concentrations

  1999cited by this paper
• Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin.

  1999cited by this paper
• Clinical management of tacrolimus drug interactions in renal transplant patients.

  1999cited by this paper
• Interaction between lovastatin and cyclosporine A after heart and kidney transplantation.

  1999cited by this paper
• Molecular and physical mechanisms of first-pass extraction.

  1999cited by this paper
• Nefazodone and cyclosporine drug-drug interaction.

  1999cited by this paper
• Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?

  1998cited by this paper
• Lack of antidepressant-cyclosporine pharmacokinetic interactions.

  1998cited by this paper
• Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics.

  1998cited by this paper
• Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group.

  1998cited by this paper
• Inhibition and Induction of Cytochrome P450 and the Clinical Implications

  1998cited by this paper
• Effects of rifampin on cyclosporine disposition in kidney recipients with tuberculosis.

  1998cited by this paper
• Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group.

  1998cited by this paper
• Tacrolimus toxic reaction associated with the use of nefazodone: paroxetine as an alternative agent.

  1998cited by this paper
• Interaction Between Tacrolimus and Nefazodone in a Stable Renal Transplant Recipient

  1998cited by this paper
• Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine‐treated kidney graft patients after multiple doses

  1997cited by this paper
• A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group.

  1997cited by this paper
• Nifedipine Interaction with Tacrolimus in Liver Transplant Recipients

  1997cited by this paper
• Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group.

  1997cited by this paper
• Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs.

  1997cited by this paper
• Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection - A report of the European Tacrolimus Multicenter Renal Study Group

  1997cited by this paper
• Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.

  1997cited by this paper
• A Comparison Of Tacrolimus (fk506) And Cyclosporine For Immunosuppression After Cadaveric Renal Transplantation1

  1997cited by this paper
• Tacrolimus—Phenytoin Interaction

  1996cited by this paper
• Methionine Loading, Vitamin B6 Status, and Premature Thromboembolic Disease

  1996cited by this paper
• Clinically Significant Drug Interactions with Cyclosporin An Update

  1996cited by this paper
• Pharmacokinetics and Bioavailability of Mycophenolate Mofetil in Healthy Subjects after Single‐Dose Oral and Intravenous Administration

  1996cited by this paper
• Fluoxetine and cyclosporine in organ transplantation. Failure to detect significant drug interactions or adverse clinical events in depressed organ recipients.

  1996cited by this paper

• Safety and efficacy of direct oral anticoagulants in kidney transplant recipients: A systematic review and meta-analysis.

  2024cites this paper
• The prevalence of medication-related problems in kidney transplant recipients at a tertiary care hospital in Saudi Arabia

  2024cites this paper
• The impact of COVID-19 on kidney transplant care

  2023cites this paper
• Drug Interactions and Safe Prescription Writing for Liver Transplant Recipients.

  2023cites this paper
• Glucocorticoids, Cyclosporine, Azathioprine, Chlorambucil, and Mycophenolate in Dogs and Cats: Clinical Uses, Pharmacology, and Side Effects.

  2022cites this paper
• Coronavirus disease 2019 and renal transplantation

  2021cites this paper
• Drug-drug interactions in patients undergoing hematopoietic stem cell transplantation: systematic review.

  2021cites this paper
• Real clinical impact of drug–drug interactions of immunosuppressants in transplant patients

  2021cites this paper
• Liver transplantation during global COVID-19 pandemic

  2021cites this paper
• Anti-rejection Medication Therapy in the Adult Solid Organ Transplant Recipient

  2020cites this paper
• Evaluation and Management of Drug-Drug Interactions in Patients Hospitalized in Nephrology and Post-Transplant Wards in a Teaching Hospital

  2020cites this paper
• Primary Care of the Solid Organ Transplant Recipient

  2020influential citation
• Interactions between anti‐infective agents and immunosuppressants—Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

  2019cites this paper
• Preventing potential drug-drug interactions through alerting decision support systems: A clinical context based methodology

  2019cites this paper
• T Cell Inhibitors

  2019cites this paper
• Exposure of a patient with systemic lupus erythematosus, under immunosuppression therapy, to human immunodeficiency virus by accidental needlestick contamination

  2018cites this paper
• Arzneimittelinteraktionen im Überblick

  2018cites this paper
• Post-transplant Psychosocial and Mental Health Care of Hematopoietic Cell Transplant Recipients

  2018cites this paper
• Ensuring Patient Safety During the Transition to ESRD.

  2017cites this paper
• Prevalence and nature of potential drug–drug interactions among kidney transplant patients in a German intensive care unit

  2017cites this paper
• Cutaneous Side Effects and Drug Interactions Related to Immunosuppressive Therapy in Solid Organ Transplantation

  2017cites this paper
• Clinical decision support systems differ in their ability to identify clinically relevant drug interactions of immunosuppressants in kidney transplant patients

  2017influential citation
• Immunosuppression in pediatric liver transplant recipients: Unique aspects

  2017cites this paper
• Induction and Standard Immunosuppression

  2017cites this paper
• Comparative DNA‐Protein Interaction and Epithelial Tight Junctions Modulation Potential of Immunosuppressive Regime

  2016cites this paper
• The role of the pharmacist in the management of kidney transplant recipients

  2016cites this paper
• Kidney Function as a Determinant of HDL and Triglyceride Concentrations in the Australian Population

  2016cites this paper
• A Systematic Approach to Assess the Burden of Drug Interactions in Adult Kidney Transplant Patients.

  2016cites this paper
• Top 10 Things Primary Care Physicians Should Know About Maintenance Immunosuppression for Transplant Recipients.

  2016cites this paper
• Safety Events in Kidney Transplant Recipients: Results from the Folic Acid for Vascular Outcome Reduction in Transplant Trial

  2015cites this paper
• General Approaches for Direct Detection and Identification of Fungi

  2015cites this paper
• Impact of pre-implant amiodarone exposure on outcomes in cardiac transplant recipients

  2015cites this paper
• Assessing pharmacologic and nonpharmacologic risks in candidates for kidney transplantation.

  2015cites this paper
• The renal dialysis and kidney transplant patient

  2015cites this paper
• Safety Events in Kidney Transplant Recipients: Results from the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) Trial

  2015cites this paper
• Cardiovascular risk factors following renal transplant.

  2015cites this paper
• Important drug classes associated with potential drug–drug interactions in critically ill patients: highlights for cardiothoracic intensivists

  2015cites this paper
• Usability of Mobile Technology to Screen for Drug-Drug Interactions in Kidney Transplant Patients

  2014cites this paper
• Non-Immunosuppressant Medication Use in Heart Transplant Patients: A Guide for Pharmacists

  2014cites this paper
• An overview of clinically significant drug interactions between medications used to treat psychiatric and medical conditions

  2014cites this paper
• Studies on the Roles of Transplant Pharmacists: Prescription Intervention for Solid Organ Transplant Inpatients

  2014cites this paper
• Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation.

  2014cites this paper
• Evaluation of eight drug interaction databases commonly used in the German healthcare system

  2014cites this paper
• Update on immununosuppressive therapies for dogs and cats.

  2013cites this paper
• Kidney transplantation down-regulates expression of organic cation transporters, which translocate β-blockers and fluoroquinolones.

  2013cites this paper
• Interactions Between Anti‐Infective Agents and Immunosuppressants in Solid Organ Transplantation

  2013cites this paper
• Quel programme informatique de détection des interactions médicamenteuses néfastes

  2012cites this paper
• Omeprazole Impairs the Absorption of Mycophenolate Mofetil But Not of Enteric‐Coated Mycophenolate Sodium in Healthy Volunteers

  2012cites this paper
• Practical Management of Boceprevir and Immunosuppressive Therapy in Liver Transplant Recipients with Hepatitis C Virus Recurrence

  2012influential citation
• Evaluation of Potential Interactions between Mycophenolic Acid Derivatives and Proton Pump Inhibitors

  2012cites this paper
• Current trends in immunosuppressive therapies for renal transplant recipients.

  2012cites this paper
• Recommendations for the proper use of nonprescription cough suppressants and expectorants in solid-organ transplant recipients.

  2011cites this paper
• Recommendations for the Proper Use of Nonprescription Cough Suppressants and Expectorants in Solid-Organ Transplant Recipients

  2011cites this paper
• Pulmonary tuberculosis in an HIV- and hepatitis C virus-coinfected kidney-pancreas transplant recipient: a case report.

  2011cites this paper
• TREPROSTINIL FOR PROTECTION OF LIVER GRAFTS AGAINST ISCHEMIA AND REPERFUSION INJURY DURING ORTHOTOPIC LIVER TRANSPLANTATION - A TRANSLATIONAL STUDY

  2011cites this paper
• Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil

  2011cites this paper
• Increasing Trend in Infection-Related Death-Censored Graft Failure in Renal Transplantation

  2011cites this paper
• Cardiovascular disease in renal transplant recipients.

  2010cites this paper
• Topics in transplantation medicine for general nephrologists.

  2010cites this paper
• Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation

  2010cites this paper
• A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation

  2010cites this paper
• Interacciones farmacológicas en trasplante

  2010cites this paper